Organic compounds -- part of the class 532-570 series – Organic compounds – Carboxylic acids and salts thereof
Patent
1998-08-04
2000-01-04
Lambkin, Deborah C.
Organic compounds -- part of the class 532-570 series
Organic compounds
Carboxylic acids and salts thereof
562433, 549452, 549493, 549 58, 549 77, 546335, 546336, 514563, 514570, 514463, 514471, 514443, 514438, 514357, C07C22900, C07D31700, A61K 31195, A61K 31335
Patent
active
060111747
DESCRIPTION:
BRIEF SUMMARY
TECHNICAL FIELD
The present invention relates novel cyclic amic acid derivatives. More particularly, the cyclic amic acid derivatives of the present invention inhibit protein-farnesyl transferase (PFT) in vivo thereby to suppress function of oncogene protein Ras and thus present antitumor activities, etc., and they are thus useful in the pharmaceutical field.
BACKGROUND ART
The ras oncogene is activated by mutation, and its translation product Ras protein plays an important role in transformation of normal cells to cancer cells. Such activation of ras oncogene is observed in many cancers such as colorectal cancers or pancreatic cancers, and the proportion thereof is reported to reach about 20% of the total human cancers. Accordingly, it is expected that canceration can be suppressed and antitumor effects can be obtained by suppressing such activation of ras oncogene, by inhibiting the function of Ras protein as its product.
Recently, it has been found that farnesyl-modification of Ras protein itself is essential for function of Ras protein, and it is possible to suppress localization of Ras protein at the plasma membrane by inhibiting this farnesyl-modification and thereby to inhibit transformation to cancer cells. The protein-farnesyl transferase (PFT) is an enzyme which catalyses this farnesyl-modification of Ras protein, and by inhibiting this enzyme, it is possible to suppress function of carcinogenic Ras protein. Further, this enzyme contributes to farnesyl-modification of only very limited proteins in vivo. Accordingly, the inhibitor for such an enzyme is expected to be a safe and highly selective antitumor agent. From such a viewpoint, many PFT inhibitors have been developed in recent years (Cell, vol. 57, p. 1167-1177 (1989); Proc. Natl. Acad. Sci., vol. 86, p. 8323-8327 (1989); ditto, vol. 90, p. 2281-2285 (1993); Science, vol. 245, p. 379-385 (1989); ditto, vol. 260, p. 1934-1937 (1993); ditto, vol. 260, p. 1937-1942 (1993); J. Biol. Chem., vol. 266, p. 15575-15578 (1991); J. Antibiotics, vol. 46, p. 222-227 (1993); Natur Medicine, vol. 1, p. 792-797 (1995); JP-A-5-201869; JP-A-5-213992).
Further, it has recently been found by a research by the present inventors that these PFT inhibitors can block the reactivation of static viruses by suppressing development of matured Ras proteins and are useful as anti-AIDS (HIV) agents (PCT/JP95/02489).
However, up to now, all of the reported PFT inhibitors have had some problems for development as medicines, such that the activities are low in cells, and the effects in vivo are inadequate.
DISCLOSURE OF THE INVENTION
It is an object of the present invention to provide a novel antitumor agent or an anti-AIDS agent which inhibits the protein-farnesyl transferase (PFT) thereby to inhibit functional manifestation of oncogene protein Ras and which thus provides antitumor or anti-AIDS effects.
The present inventors have found that a compound of the formula (I): ##STR3## wherein ##STR4## is an aryl group or a heteroaromatic ring group which may have substituent(s) selected from the group consisting of a halogen atom, a hydroxyl group, an amino group, a nitro group, a cyano group, a carboxyl group, a lower alkoxycarbonyl group, a carbamoyl group, a lower alkylcarbamoyl group, a lower alkyl group, a lower alkenyl group, a lower hydroxyalkyl group, a lower fluoroalkyl group, a lower alkoxy group, an aryl group and a heteroaromatic ring group; ##STR5## is a group of the formula ##STR6## when Q.sup.2 is a single bond, or a group of the formula ##STR7## when Q.sup.2 is a group of the formula --(CH.sub.2).sub.m -- or --(CH.sub.2).sub.n --W--(CH.sub.2).sub.p --; each of ##STR8## which are the same or different, is an aryl group or a heteroaromatic ring group which may have substituent(s) selected from the group consisting of a halogen atom, a hydroxyl group, an amino group, a nitro group, a cyano group, a carboxyl group, a lower alkoxycarbonyl group, a lower alkylamino group, a carbamoyl group, a lower alkylcarbamoyl group, a lower alkyl group, a lower alkenyl group,
REFERENCES:
patent: 3855248 (1974-12-01), Lannert et al.
patent: 4182718 (1980-01-01), Crutchfield et al.
patent: 5488149 (1996-01-01), Nomoto et al.
patent: 5606101 (1997-02-01), Nomoto et al.
patent: 5616803 (1997-04-01), Nomoto et al.
patent: 5643958 (1997-07-01), Iwasawa et al.
patent: 5777150 (1998-07-01), Nomoto et al.
Chemical Abstracts, vol. 60, No. 10, May 11, 1964, Abstract No. 11924g.
Aoyama Tetsuya
Arai Sachie
Iwasawa Yoshikazu
Kawakami Kumiko
Monden Yoshiaki
Banyu Pharmaceutical Co. Ltd.
Lambkin Deborah C.
LandOfFree
Cyclic amic acid derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cyclic amic acid derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclic amic acid derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1073788